HE
HEPA.US Hepion Pharmaceuticals Inc
- Market cap
- USD 14.0M
- P/E
- -
- P/B
- 41.86x
- ROE
- -322.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is HEPA.US undervalued?
Graham numberThe Graham number of Hepion Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hepion Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Hepion Pharmaceuticals Inc yet.
Hepion Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosi…
Full company profileHepion Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hepion Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -21.5K | -21.9K | -18.8K | -26.7K | -34.5K | -86.1K | -77.5K | -67.1K | -30.8K | - | - |
| Operating Income | -20.8M | -21.0M | -14.6M | -7.77M | -20.1M | -30.4M | -45.5M | -48.4M | -19.3M | -4.16M | -4.02M |
| EBITDA | -20.8M | -20.6M | -14.6M | -7.74M | -20.1M | -32.6M | -45.0M | -49.3M | -14.9M | -3.73M | -4.04M |
| Net Income | -17.0M | -15.0M | -9.45M | -7.04M | -20.4M | -32.7M | -42.2M | -48.9M | -13.2M | -8.28M | -4.12M |
| EPS | -354,138 | -108,856 | -51,355 | -3,445 | -2,103 | -466 | -554 | -12 | -107 | -0.88 | -0.25 |
| Balance Sheet | |||||||||||
| Total Assets | 13.1M | 11.3M | 8.19M | 20.6M | 48.6M | 104M | 60.2M | 18.1M | 1.61M | 3.07M | 1.93M |
| Total Liabilities | 11.8M | 7.55M | 6.21M | 4.99M | 8.12M | 10.6M | 10.4M | 10.8M | 3.48M | 402K | 649K |
| Shareholders' Equity | 1.32M | 3.70M | 1.98M | 15.6M | 40.5M | 93.0M | 49.9M | 7.28M | -1.86M | 2.67M | 1.28M |
| Cash & Short-term Investments | 7.40M | 5.95M | 2.83M | 13.9M | 40.7M | 91.3M | 51.2M | 14.8M | 406K | 1.83M | 1.63M |
| Total Debt | 10.4K | - | 1.44M | 807K | 752K | 317K | 53.6K | 209K | 2.90M | 54.1K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.6M | -8.21M | -15.6M | -7.57M | -16.2M | -31.2M | -35.0M | -40.9M | -18.2M | -3.27M | -1.63M |
| Capital Expenditure | 6.60K | 2.43 | 51.5K | 51.5K | 88.0K | 130K | 16.3K | 14.3K | 14.3K | 0.00 | 16.00 |
| Free Cash Flow | -16.6M | -8.21M | -15.6M | -7.62M | -16.3M | -31.4M | -35.0M | -40.9M | -18.2M | -3.27M | -1.63M |
| Ratios | |||||||||||
| ROE | -1,290.1% | -405.7% | -478.4% | -45.1% | -50.2% | -35.2% | -84.6% | -672.0% | - | -310.3% | -322.1% |
| ROA | -129.7% | -133.5% | -115.4% | -34.1% | -41.8% | -31.6% | -70.0% | -270.4% | -817.5% | -269.6% | -213.7% |
| Debt to Equity | 0.01x | - | 0.73x | 0.05x | 0.02x | 0.00x | 0.00x | 0.03x | - | 0.02x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hepion Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 1.00K | 0.00 | - |
| 2022 | USD 5.00K | 0.07 | - |
| 2021 | USD 11.0K | 0.16 | - |
| 2020 | USD 10.0K | 1.03 | - |
| 2019 | USD 147K | 72 | - |
| 2018 | USD 4.68M | 25,436 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:50 on Mar 18, 2025.
Who owns Hepion Pharmaceuticals Inc
- Insiders 63.30%
- Institutions 0.00%
- Public & others 36.70%
- Shares outstanding 123M
- Free float 18.4M
Top funds holding HEPA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Extended Equity Market Fund B | 292.00 | 0.00% | 0.00% | Dec 2025 |
| BlackRock Extended Equity Market Fund K | 248.00 | 0.00% | 0.00% | Jun 2026 |
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 54.00 | 0.00% | -6.90% | Jun 2026 |
| Extended Equity Market Fund M | 30.00 | 0.00% | +3.45% | Jun 2026 |
| NT Ext Eq Mkt Idx Fd DC Lending Tier 5 | 26.00 | 0.00% | 0.00% | Mar 2026 |
Top institutions holding HEPA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Sep 2025 |
Hepion Pharmaceuticals Inc company profile
- Company name
- Hepion Pharmaceuticals Inc
- Ticker
- HEPA.US
- Exchange
- USA Stocks
- Listed since
- Feb 11, 2014
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2
- Fiscal year end
- December
- Address
- 55 Madison Avenue, Morristown, NJ, United States, 07960
- Phone
- 732 902 4000
- Website
- hepionpharma.com
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. It also operates as a biotech research development company. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Hepion Pharmaceuticals Inc management
4- Mr. Vincent LoPrioreExecutive Chairman · born 1968
- Dr. Sireesh Appajosyula Pharm.D.CEO & Director · born 1975
- Mr. Gary S. Stetz CPACFO & Director · born 1963
- Sharen PyatetskayaDirector of Investor Relations